Personalised oncology: innovative people centred, multi-modal therapies against cancer
The HORIZON-JU-IHI-2022-01-03 call, part of the Innovative Health Initiative (IHI) Joint Undertaking under Horizon Europe, aimed to accelerate the development of personalized, multi-modal cancer therapies. This initiative sought to integrate diverse health research and innovation efforts, focusing on unmet public health needs and fostering solutions that seamlessly fit into healthcare systems for improved patient outcomes.
Who is Funded
This section outlines the general eligibility criteria for funding, including the types of organizations and geographic areas covered, along with the program's strategic objectives in advancing cancer therapies.
What is Funded
This section provides details on the types of projects and thematic areas eligible for funding, focusing on cancer research, diagnostics, and therapy development. It also clarifies general guidelines regarding eligible costs.
Type and Scope of Funding
This section outlines the financial aspects of the program, including the type of funding instrument and the expected funding amounts available per project and for the overall call.
Conditions and Requirements
This section details the critical rules and stipulations that applicants and beneficiaries must adhere to, covering application terms, collaboration requirements, and other specific provisions.
Application Procedure
This section guides potential applicants through the submission process, outlining the steps for application preparation and submission, and explaining how proposals are evaluated.
Legal Basis
This section identifies the foundational legal and official documents that establish and govern the funding program, ensuring transparency regarding its operational framework.
Similar Programs
Funding Overview
Funding Status:
Closed
Maximum Amount:
20.000.000 €
Allocated Budget:
The overall budget for the call (HORIZON-JU-IHI-2022-01-single-stage) was 135,000,000 € for 2022. For this specific topic (HORIZON-JU-IHI-2022-01-03), individual grants were expected to range from 10,000,000 € to 20,000,000 €, with two grants anticipated, totaling between 20,000,000 € and 40,000,000 € for the topic.
Award Channel:
Framework Programme Call
Region:
European Union Member States and Associated Countries, potentially other countries with specific funding provisions.
Sectors:
Healthcare, Medical Technology, Pharmaceutical Industry, Research and Development, Other
Application Type:
Consortium Required
Funding Stages:
Applied Research, Experimental Development, Pilot Testing, Product Development
Funding Provider
Program Level:
European Union
Funding Body:
European Commission, Innovative Health Initiative Joint Undertaking (IHI JU)
Managed By:
Innovative Health Initiative Joint Undertaking (IHI JU)
Additional Partners:
Various academic institutions, research organizations, private companies (including SMEs), and hospitals across Europe and associated countries have offered expertise for this topic, such as the University of Jaen (Spain), TRON (Germany), C4G (Portugal), and SYNYO GmbH (Austria).
Website: